Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
Type:
Grant
Filed:
June 28, 2022
Date of Patent:
April 18, 2023
Assignees:
New York University, PureTech Health, LLC
Inventors:
Shohei Koide, George Miller, Akiko Koide, Linxiao Chen, Eric Elenko, Aleksandra Filipovic, Joseph Bolen
Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
Type:
Grant
Filed:
September 19, 2019
Date of Patent:
August 16, 2022
Assignees:
New York University, PureTech Health, LLC
Inventors:
Shohei Koide, George Miller, Akiko Koide, Linxiao Chen, Eric Elenko, Aleksandra Filipovic, Joseph Bolen
Abstract: The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline salt and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period, the central nervous system disorder being selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline salt.
Type:
Grant
Filed:
June 18, 2019
Date of Patent:
June 30, 2020
Assignee:
PureTech Health LLC
Inventors:
Eric Elenko, Philip E. Murray, III, Andrew C. Miller
Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
Type:
Grant
Filed:
May 8, 2019
Date of Patent:
October 22, 2019
Assignees:
New York University, PureTech Health, LLC
Inventors:
Shohei Koide, George Miller, Akiko Koide, Linxiao Chen, Eric Elenko, Aleksandra Filipovic, Joseph Bolen
Abstract: Provided herein is a method of treating a central nervous system disorder in a patient in need thereof, wherein the central nervous system disorder is selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia. The method comprises orally administering an initial dose of between 75 mg and 300 mg xanomeline and an initial dose of between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period. Provided that the patient tolerates said administration, an increased dose of trospium chloride and an increased dose of xanomeline are orally administering to the patient, wherein the increased dose of trospium chloride is greater than the initial dose of the trospium chloride, and wherein the increased dose of xanomeline is greater than the initial dose of the xanomeline.
Type:
Grant
Filed:
February 7, 2019
Date of Patent:
August 6, 2019
Assignee:
PureTech Health LLC
Inventors:
Eric Elenko, Philip E. Murray, III, Andrew C. Miller
Abstract: The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period. The central nervous system disorder is selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline.
Type:
Grant
Filed:
February 28, 2019
Date of Patent:
August 6, 2019
Assignee:
PureTech Health LLC
Inventors:
Eric Elenko, Philip E. Murray, III, Andrew C. Miller
Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
Type:
Grant
Filed:
October 29, 2018
Date of Patent:
July 9, 2019
Assignees:
New York University, PureTech Health, LLC
Inventors:
Shohei Koide, George Miller, Akiko Koide, Linxiao Chen, Eric Elenko, Aleksandra Filipovic, Joseph Bolen
Abstract: Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.
Type:
Grant
Filed:
December 14, 2016
Date of Patent:
April 23, 2019
Assignee:
PureTech Health LLC
Inventors:
Eric Elenko, Andrew C. Miller, Philip E. Murray, III
Abstract: Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.
Type:
Grant
Filed:
January 6, 2017
Date of Patent:
March 26, 2019
Assignee:
PureTech Health LLC
Inventors:
Eric Elenko, Philip E. Murray, III, Andrew C. Miller